U.S. Food and Drug Administration | MIDD Training Module 4 – Foundation to Model Informed Drug Development and Model Interconnectedness @US_FDA | Uploaded 2 months ago | Updated 1 hour ago
This lecture by Drs. Adekemi, Taylor, Rajesh Krishna and S.Y. Amy Cheung, Senior Directors of Integrated Drug Development at Certara, explores the foundational principles underlying Model-Informed Drug Development (MIDD).
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.
This lecture by Drs. Adekemi, Taylor, Rajesh Krishna and S.Y. Amy Cheung, Senior Directors of Integrated Drug Development at Certara, explores the foundational principles underlying Model-Informed Drug Development (MIDD).
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.
